Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay

Sponsor
Virginia Polytechnic Institute and State University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04816175
Collaborator
American Academy for Cerebral Palsy and Developmental Medicine (Other)
4
1
1
38
0.1

Study Details

Study Description

Brief Summary

This trial will consist of a clinical series of up to 50 children with Global Developmental Delay and concomitant microcephaly or hyperkinetic movements. All children will be assessed for psychomotor function using standardized assessments, goal specific assessments, with the potential addition of neuroimaging assessment, prior to and after receiving an intensive burst of neuromotor therapy. The interventional effects will be explored by comparing the pre and post interventional assessments and neuroimaging.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Acquire Therapy
N/A

Detailed Description

Up to 50 children between the ages of 6 months and 15 years will be recruited to participate in a burst of intensive neuromotor intervention in the form of Acquire therapy, delivered by the treatment team at Virginia Tech's Neuromotor Research Clinic. All children will have a diagnosis of Global Developmental Delay, with concomitant microcephaly or hyperkinetic movements. The children will be assessed for psychomotor function prior to and after the treatment intervention, using a series of standardized and goal specific assessments, with the possibility of additional neuroimaging assessments when possible. Acquire therapy is an intensive intervention in that it is delivered with high intensity, wherein goal directed behaviors are promoted at high levels of repetition and delivered at a high dose (4-6 hours a day) in an intensive burst of 3-4 weeks of 5 day a week treatment. Acquire therapy is an operant conditioning based intervention delivered in a cycle of refinement, reinforcement and repetition. It is play-based with activities selected to drive behavior toward goals that are specific to each child and selected based on each child's interests and needs. As such a specific protocol cannot be outlined. However, all goal directed activities are designed to promote awareness of and engagement with others and the environment.

Study Design

Study Type:
Interventional
Actual Enrollment :
4 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
As an early phase study, all enrolled children will receive the intervention.As an early phase study, all enrolled children will receive the intervention.
Masking:
None (Open Label)
Masking Description:
Because all children will receive the intervention all parties involved will be aware that the participant has received the intervention.
Primary Purpose:
Treatment
Official Title:
Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay
Actual Study Start Date :
Apr 30, 2019
Actual Primary Completion Date :
Dec 30, 2021
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment Intervention

All children will receive 3-5 weeks of intensive neuromotor Acquire therapy, an operant conditioning, play based therapy that maximizes therapeutic movements, attention, and engagement.

Behavioral: Acquire Therapy
This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function

Outcome Measures

Primary Outcome Measures

  1. Change from baseline on Motor Function Assessment [5-12 weeks]

    A validated motor function assessment tool the CanChild Gross Motor Function Measure -88 will be used to measure change on motor function. The child can score between 0 and 264 points. The higher the child's score the more tasks they were able to attempt and/or complete.

Secondary Outcome Measures

  1. Change from baseline on measure of EEG coherence in alpha band [5-12 weeks]

    EEG data will be analyzed for changes in coherence in alpha band. Pre and post coherence in alpha band will be probed for changes by electrode pair.

  2. Change from baseline on measure of EEG coherence in theta band. [5-12 weeks]

    EEG data will be analyzed for changes in coherence in theta band. Pre and post coherence in theta band will be probed for changes by electrode pair.

  3. Change from baseline on measure of EEG coherence in beta band. [5-12 weeks]

    EEG data will be analyzed for changes in coherence in beta band. Pre and post coherence in beta band will be probed for changes by electrode pair.

  4. Change from baseline on measure of EEG coherence in delta band. [5-12 weeks]

    EEG data will be analyzed for changes in coherence in delta band. Pre and post coherence in delta band will be probed for changes by electrode pair.

  5. Change from baseline on EEG power in alpha band. [5-12 weeks]

    EEG data will be analyzed for changes in power in alpha band. Pre and post power will be compared for alpha band.

  6. Change from baseline on EEG power in beta band. [5-12 weeks]

    EEG data will be analyzed for changes in power in beta bands. Pre and post power will be compared for beta band.

  7. Change from baseline on EEG power in theta band. [5-12 weeks]

    EEG data will be analyzed for changes in power in theta band. Pre and post power will be compared for theta band.

  8. Change from baseline on EEG power in delta bands. [5-12 weeks]

    EEG data will be analyzed for changes in power in delta bands. Pre and post power will be compared for delta band.

  9. Change from baseline on Disability Assessment [5-12 weeks]

    Using the Pediatric evaluation of disability inventory with scores ranging from 0-100 with higher scored indicating greater functionality.

  10. Change from baseline on fMRI measures of connectivity [5-12 weeks]

    fMRI data will be probed for change from baseline on measures of connectivity.

  11. Change from baseline on fMRI regional activation patterns. [5-12 weeks]

    fMRI data will be probed for change from baseline on measures of regional activation.

  12. Change from baseline on Motor Assessment [5-12 weeks]

    Using the Peabody Developmental Motor Scales, the Peabody consists of 6 subtests, that are each completed according to the child's age as a starting point. If a child were to complete all 6 subtests, and were to start at the earliest age block for all subtests the child would complete 255 items, with scores ranging from 0-510, the higher the score the more tasks the child was able to complete.

  13. Change from baseline on goal specific assessment [5-12 weeks]

    Using a goal specific assessment form developed in the neuromotor research clinic children will be assessed for changes on child specific goals using a metric goal attainment assessment method (See Mann, J 2020 Dev Neurorehab). The child will be measured on their percent change on child-specific goals, with ranges from 0 percent change to infinity percent change. The higher the percent change the more the child changed on that particular goal.

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Months to 15 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of Global Developmental Delay with Microcephaly or hyperkinetic movements.
Exclusion Criteria:
  • Medical Instability

  • Under 6 months of age over 15 years of age

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fralin Biomedical Research Institute at Virginia Tech Roanoke Virginia United States 24016

Sponsors and Collaborators

  • Virginia Polytechnic Institute and State University
  • American Academy for Cerebral Palsy and Developmental Medicine

Investigators

  • Principal Investigator: Stephanie C DeLuca, PhD, Virginia Polytechnic Institute and State University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Stephanie DeLuca, Principal Investigator, Virginia Polytechnic Institute and State University
ClinicalTrials.gov Identifier:
NCT04816175
Other Study ID Numbers:
  • IRB #18-490
First Posted:
Mar 25, 2021
Last Update Posted:
Mar 8, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Stephanie DeLuca, Principal Investigator, Virginia Polytechnic Institute and State University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2022